| Year |
Citation |
Score |
| 2019 |
Falk DE, O'Malley SS, Witkiewitz K, Anton RF, Litten RZ, Slater M, Kranzler HR, Mann KF, Hasin DS, Johnson B, Meulien D, Ryan M, Fertig J. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. Jama Psychiatry. PMID 30865232 DOI: 10.1001/Jamapsychiatry.2018.3079 |
0.392 |
|
| 2017 |
Johnson BA. Towards rational, evidence-based, and clinically relevant measures to determine improvement following treatment for alcohol use disorder. Alcoholism, Clinical and Experimental Research. PMID 28118502 DOI: 10.1111/acer.13341 |
0.321 |
|
| 2016 |
Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, et al. A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27658483 DOI: 10.1038/Npp.2016.214 |
0.504 |
|
| 2015 |
Seneviratne C, Johnson BA. Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. Alcohol Research : Current Reviews. 37: 15-28. PMID 26259086 |
0.353 |
|
| 2015 |
Hou J, Seneviratne C, Su X, Taylor J, Johnson B, Wang XQ, Zhang H, Kranzler HR, Kang J, Liu L. Subgroup Identification in Personalized Treatment of Alcohol Dependence. Alcoholism, Clinical and Experimental Research. 39: 1253-9. PMID 26031187 DOI: 10.1111/acer.12759 |
0.334 |
|
| 2014 |
Johnson BA, Seneviratne C. Alcohol-medical drug interactions. Handbook of Clinical Neurology. 125: 543-59. PMID 25307595 DOI: 10.1016/B978-0-444-62619-6.00031-8 |
0.35 |
|
| 2014 |
Falk DE, Litten RZ, Anton RF, Kranzler HR, Johnson BA. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. Journal of Studies On Alcohol and Drugs. 75: 335-46. PMID 24650828 |
0.424 |
|
| 2014 |
Moore CF, Lycas MD, Bond CW, Johnson BA, Lynch WJ. Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats. Experimental and Clinical Psychopharmacology. 22: 35-42. PMID 24490709 DOI: 10.1037/A0035215 |
0.452 |
|
| 2014 |
Moore CF, Protzuk OA, Johnson BA, Lynch WJ. The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. Pharmacology, Biochemistry, and Behavior. 116: 107-15. PMID 24252444 DOI: 10.1016/J.Pbb.2013.11.013 |
0.398 |
|
| 2013 |
Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, Liu L. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. Jama Psychiatry. 70: 1338-46. PMID 24132249 DOI: 10.1001/Jamapsychiatry.2013.2295 |
0.346 |
|
| 2013 |
Johnson BA, Seneviratne C, Wang XQ, Ait-Daoud N, Li MD. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. The American Journal of Psychiatry. 170: 1020-31. PMID 23897038 DOI: 10.1176/Appi.Ajp.2013.12091163 |
0.458 |
|
| 2013 |
Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. Journal of Addiction Medicine. 7: 277-86. PMID 23728065 DOI: 10.1097/Adm.0B013E31829623F4 |
0.527 |
|
| 2013 |
Ma JZ, Johnson BA, Yu E, Weiss D, McSherry F, Saadvandi J, Iturriaga E, Ait-Daoud N, Rawson RA, Hrymoc M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, et al. Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis. Drug and Alcohol Dependence. 130: 45-51. PMID 23142494 DOI: 10.1016/J.Drugalcdep.2012.10.009 |
0.359 |
|
| 2013 |
Johnson BA, Roache JD, Ait-Daoud N, Gunderson EW, Haughey HM, Wang XQ, Liu L. Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking. Addiction Biology. 18: 405-16. PMID 23039088 DOI: 10.1111/J.1369-1600.2012.00499.X |
0.301 |
|
| 2013 |
Chen J, Liu L, Johnson BA, O'Quigley J. Penalized likelihood estimation for semiparametric mixed models, with application to alcohol treatment research. Statistics in Medicine. 32: 335-46. PMID 22833388 DOI: 10.1002/Sim.5528 |
0.316 |
|
| 2013 |
Johnson B, Seneviratne C, Franklin J, Beckett K, Ma J, Ait-Daoud N, Payne T, Johnson B, Li M, Ait-Daoud N, Kenna G, Zywiak WH, McGeary JE, Swift RM, Clifford JS, et al. S02 * SEROTONIN SYSTEM IN ALCOHOLISM: INDIVIDUAL DIFFERENCES AND TREATMENT Alcohol and Alcoholism. 48: i3-i4. DOI: 10.1093/Alcalc/Agt074 |
0.484 |
|
| 2012 |
Wages NA, Liu L, O'Quigley J, Johnson BA. Obtaining the optimal dose in alcohol dependence studies. Frontiers in Psychiatry. 3: 100. PMID 23189064 DOI: 10.3389/Fpsyt.2012.00100 |
0.447 |
|
| 2012 |
Chen J, Johnson BA, Wang XQ, O'Quigley J, Isaac M, Zhang D, Liu L. Trajectory analyses in alcohol treatment research. Alcoholism, Clinical and Experimental Research. 36: 1442-8. PMID 22525000 DOI: 10.1111/J.1530-0277.2012.01748.X |
0.44 |
|
| 2012 |
Liu L, Strawderman RL, Johnson BA, O'Quigley JM. Analyzing repeated measures semi-continuous data, with application to an alcohol dependence study. Statistical Methods in Medical Research. PMID 22474003 DOI: 10.1177/0962280212443324 |
0.333 |
|
| 2012 |
Seneviratne C, Johnson BA. Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics. Frontiers in Psychiatry. 3: 23. PMID 22470354 DOI: 10.3389/Fpsyt.2012.00023 |
0.492 |
|
| 2012 |
Vaughan MD, Hook JN, Wagley JN, Davis D, Hill C, Johnson BA, Penberthy JK. Changes in Affect and Drinking Outcomes in a Pharmacobehavioral Trial for Alcohol Dependence. Addictive Disorders & Their Treatment. 11: 14-25. PMID 22368517 DOI: 10.1097/Adt.0B013E31821E1072 |
0.467 |
|
| 2012 |
Ait-Daoud N, Seneviratne C, Smith JB, Roache JD, Dawes MA, Liu L, Wang XQ, Johnson BA. Preliminary Evidence for cue-induced Alcohol Craving Modulated by Serotonin Transporter Gene Polymorphism rs1042173. Frontiers in Psychiatry. 3: 6. PMID 22355291 DOI: 10.3389/Fpsyt.2012.00006 |
0.445 |
|
| 2012 |
Kovatchev B, Breton M, Johnson B. In silico Models of Alcohol Dependence and Treatment. Frontiers in Psychiatry. 3: 4. PMID 22347195 DOI: 10.3389/Fpsyt.2012.00004 |
0.476 |
|
| 2012 |
Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcoholism, Clinical and Experimental Research. 36: 1421-30. PMID 22324516 DOI: 10.1111/J.1530-0277.2011.01716.X |
0.53 |
|
| 2012 |
Elkashef A, Kahn R, Yu E, Iturriaga E, Li SH, Anderson A, Chiang N, Ait-Daoud N, Weiss D, McSherry F, Serpi T, Rawson R, Hrymoc M, Weis D, McCann M, ... ... Johnson BA, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction (Abingdon, England). 107: 1297-306. PMID 22221594 DOI: 10.1111/J.1360-0443.2011.03771.X |
0.417 |
|
| 2012 |
Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcoholism, Clinical and Experimental Research. 36: 406-16. PMID 21950727 DOI: 10.1111/J.1530-0277.2011.01649.X |
0.507 |
|
| 2012 |
Kovatchev B, Breton M, Johnson B. In silico models of alcohol dependence and treatment Frontiers in Psychiatry. 3. DOI: 10.3389/fpsyt.2012.00004 |
0.38 |
|
| 2011 |
Penberthy JK, Hook JN, Vaughan MD, Davis DE, Wagley JN, Diclemente CC, Johnson BA. Impact of motivational changes on drinking outcomes in pharmacobehavioral treatment for alcohol dependence. Alcoholism, Clinical and Experimental Research. 35: 1694-704. PMID 21676008 DOI: 10.1111/J.1530-0277.2011.01516.X |
0.484 |
|
| 2011 |
Johnson BA, Messing RO, Charness ME, Crabbe JC, Goldman MS, Harris RA, Kranzler HR, Jr MC, Nixon SJ, Riley EP, Schuckit MA, Sher KJ, Thomas JD. How Should Addiction-Related Research at the National Institutes of Health be Reorganized? Frontiers in Psychiatry. 2: 2. PMID 21629835 DOI: 10.3389/Fpsyt.2011.00002 |
0.464 |
|
| 2011 |
Johnson BA, Messing RO, Charness ME, Crabbe JC, Goldman MS, Harris RA, Kranzler HR, Mitchell MC, Nixon SJ, Riley EP, Schuckit MA, Sher KJ, Thomas JD. Should the reorganization of addiction-related research across all the National Institutes of Health be structural?--The devil is truly in the details. Alcoholism, Clinical and Experimental Research. 35: 572-80. PMID 21443646 DOI: 10.1111/J.1530-0277.2011.01493.X |
0.433 |
|
| 2011 |
Lynch WJ, Bond C, Breslin FJ, Johnson BA. Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. Psychopharmacology. 217: 3-12. PMID 21424693 DOI: 10.1007/S00213-011-2253-0 |
0.457 |
|
| 2011 |
Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. The American Journal of Psychiatry. 168: 265-75. PMID 21247998 DOI: 10.1176/Appi.Ajp.2010.10050755 |
0.412 |
|
| 2011 |
Johnson BA. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking (American Journal of Psychiatry (2011) 168 (265-275)) American Journal of Psychiatry. 168: 756. DOI: 10.1176/appi.ajp.2011.168.7.756 |
0.336 |
|
| 2011 |
Tiouririne NA, Johnson B, Lynch W, Bond C, Breslin FJ, Johnson BA. S21 * GENETIC DIFFERENCES AT THE SEROTONIN TRANSPORTER GENE PROMISE A PHARMACOGENETIC APPROACH TO THE USE OF ONDANSETRON WITH AND WITHOUT OTHER AGENTS TO TREAT ALCOHOLISM * S21.1 * POLYMORPHISM OF THE SNP IN THE 3'-UNTRANSLATED REGION OF THE SEROTONIN TRANSPORTER GENE DIFFERENTIALLY AFFECT ALCOHOL CRAVING Alcohol and Alcoholism. 46: i19-i20. DOI: 10.1093/Alcalc/Agr111 |
0.419 |
|
| 2010 |
Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, Johnson B, Stout R, Litten RZ. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcoholism, Clinical and Experimental Research. 34: 2022-34. PMID 20659066 DOI: 10.1111/J.1530-0277.2010.01290.X |
0.463 |
|
| 2010 |
Johnson BA. Medication treatment of different types of alcoholism. The American Journal of Psychiatry. 167: 630-9. PMID 20516163 DOI: 10.1176/Appi.Ajp.2010.08101500 |
0.461 |
|
| 2010 |
Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Current Pharmaceutical Design. 16: 2103-12. PMID 20482511 DOI: 10.2174/138161210791516404 |
0.508 |
|
| 2010 |
Breslin FJ, Johnson BA, Lynch WJ. Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology. 207: 529-34. PMID 19823810 DOI: 10.1007/S00213-009-1683-4 |
0.376 |
|
| 2009 |
Dawes MA, Roache JD, Javors MA, Bergeson SE, Richard DM, Mathias CW, Ait-Daoud N, Dougherty DM, Johnson BA. Drinking histories in alcohol-use-disordered youth: preliminary findings on relationships to platelet serotonin transporter expression with genotypes of the serotonin transporter. Journal of Studies On Alcohol and Drugs. 70: 899-907. PMID 19895766 DOI: 10.15288/Jsad.2009.70.899 |
0.408 |
|
| 2009 |
Seneviratne C, Ait-Daoud N, Ma JZ, Chen G, Johnson BA, Li MD. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 2442-9. PMID 19553914 DOI: 10.1038/Npp.2009.65 |
0.401 |
|
| 2009 |
Ait-Daoud N, Roache JD, Dawes MA, Liu L, Wang XQ, Javors MA, Seneviratne C, Johnson BA. Can serotonin transporter genotype predict craving in alcoholism? Alcoholism, Clinical and Experimental Research. 33: 1329-35. PMID 19426172 DOI: 10.1111/J.1530-0277.2009.00962.X |
0.373 |
|
| 2009 |
Seneviratne C, Huang W, Ait-Daoud N, Li MD, Johnson BA. Characterization of a functional polymorphism in the 3' UTR of SLC6A4 and its association with drinking intensity. Alcoholism, Clinical and Experimental Research. 33: 332-9. PMID 19032574 DOI: 10.1111/J.1530-0277.2008.00837.X |
0.37 |
|
| 2008 |
Roache JD, Wang Y, Ait-Daoud N, Johnson BA. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism. Alcoholism, Clinical and Experimental Research. 32: 1502-12. PMID 18565156 DOI: 10.1111/J.1530-0277.2008.00717.X |
0.432 |
|
| 2008 |
Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Archives of Internal Medicine. 168: 1188-99. PMID 18541827 DOI: 10.1001/Archinte.168.11.1188 |
0.444 |
|
| 2008 |
Liu L, Ma JZ, Johnson BA. A multi-level two-part random effects model, with application to an alcohol-dependence study. Statistics in Medicine. 27: 3528-39. PMID 18219701 DOI: 10.1002/Sim.3205 |
0.428 |
|
| 2008 |
Johnson BA, Javors MA, Roache JD, Seneviratne C, Bergeson SE, Ait-Daoud N, Dawes MA, Ma JZ. Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking? Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 209-16. PMID 17950969 DOI: 10.1016/J.Pnpbp.2007.07.030 |
0.336 |
|
| 2008 |
Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochemical Pharmacology. 75: 34-56. PMID 17880925 DOI: 10.1016/J.Bcp.2007.08.005 |
0.516 |
|
| 2008 |
Johnson BA, Ait-Daoud N, Elkashef AM, Smith EV, Kahn R, Vocci F, Li SH, Bloch DA. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 11: 1-14. PMID 17470315 DOI: 10.1017/S1461145707007778 |
0.377 |
|
| 2008 |
Johnson BA, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM. Topiramate as treatment for alcohol dependence: Reply [4] Jama - Journal of the American Medical Association. 299: 406-407. DOI: 10.1001/Jama.299.4.406 |
0.503 |
|
| 2007 |
Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Therapeutics and Clinical Risk Management. 3: 741-9. PMID 18472999 |
0.389 |
|
| 2007 |
Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. Jama. 298: 1641-51. PMID 17925516 DOI: 10.1001/Jama.298.14.1641 |
0.513 |
|
| 2007 |
Penberthy JK, Ait-Daoud N, Breton M, Kovatchev B, DiClemente CC, Johnson BA. Evaluating readiness and treatment seeking effects in a pharmacotherapy trial for alcohol dependence. Alcoholism, Clinical and Experimental Research. 31: 1538-44. PMID 17624996 DOI: 10.1111/J.1530-0277.2007.00448.X |
0.472 |
|
| 2007 |
Johnson BA, Wells LT, Roache JD, Wallace CL, Ait-Daoud N, Dawes MA, Liu L, Wang XQ, Javors MA. Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31: 455-61. PMID 17184890 DOI: 10.1016/J.Pnpbp.2006.11.011 |
0.339 |
|
| 2007 |
Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang XQ. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 10: 85-98. PMID 16448579 DOI: 10.1017/S1461145705006401 |
0.416 |
|
| 2007 |
Johnson BA. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine: Implications for the treatment of nicotine and alcohol dependence Translation of Addictions Science Into Practice. 169-185. DOI: 10.1016/B978-008044927-2/50058-4 |
0.385 |
|
| 2006 |
Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction (Abingdon, England). 101: 1561-8. PMID 17034435 DOI: 10.1111/J.1360-0443.2006.01576.X |
0.467 |
|
| 2006 |
Johnson BA. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. Expert Opinion On Pharmacotherapy. 7: 1065-73. PMID 16722816 DOI: 10.1517/14656566.7.8.1065 |
0.515 |
|
| 2006 |
Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. Jama. 295: 2003-17. PMID 16670409 DOI: 10.1001/Jama.295.17.2003 |
0.448 |
|
| 2006 |
Johnson BA, Roache JD, Ait-Daoud N, Javors MA, Harrison JM, Elkashef A, Mojsiak J, Li SH, Bloch DA. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug and Alcohol Dependence. 84: 256-63. PMID 16631323 DOI: 10.1016/J.Drugalcdep.2006.02.011 |
0.347 |
|
| 2006 |
Johnson BA, Koob GF, Schuckit MA, Mason BJ, Ait-Daoud N. Understanding and treating alcohol dependence. Alcoholism, Clinical and Experimental Research. 30: 567-84. PMID 16499499 DOI: 10.1111/J.1530-0277.2005.00066.X |
0.499 |
|
| 2006 |
Ait-Daoud N, Malcolm RJ, Johnson BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants. Addictive Behaviors. 31: 1628-49. PMID 16472931 DOI: 10.1016/J.Addbeh.2005.12.029 |
0.529 |
|
| 2005 |
Roache JD, Johnson BA, Ait-Daoud N, Mauldin JB, Thornton JE, Wells LT, Murff WL. Effects of repeated-dose isradipine on the abuse liability of cocaine. Experimental and Clinical Psychopharmacology. 13: 319-26. PMID 16366762 DOI: 10.1037/1064-1297.13.4.319 |
0.301 |
|
| 2005 |
Johnson BA, Ait-Daoud N, Roache JD. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. Journal of Studies On Alcohol. Supplement. 157-67; discussion 1. PMID 16223067 DOI: 10.15288/Jsas.2005.S15.157 |
0.456 |
|
| 2005 |
Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. Cns Drugs. 19: 873-96. PMID 16185095 DOI: 10.2165/00023210-200519100-00005 |
0.442 |
|
| 2005 |
Ait-Daoud N, Wiesbeck GA, Bienkowski P, Li MD, Pfützer RH, Singer MV, Lesch OM, Johnson BA. Comorbid alcohol and nicotine dependence: from the biomolecular basis to clinical consequences. Alcoholism, Clinical and Experimental Research. 29: 1541-9. PMID 16156051 DOI: 10.1097/01.Alc.0000174692.20933.49 |
0.477 |
|
| 2005 |
Johnson BA, Mann K, Willenbring ML, Litten RZ, Swift RM, Lesch OM, Berglund M. Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. Alcoholism, Clinical and Experimental Research. 29: 1528-40. PMID 16156050 DOI: 10.1097/01.Alc.0000174690.63787.Fc |
0.414 |
|
| 2005 |
Wurst FM, Tabakoff B, Alling C, Aradottir S, Wiesbeck GA, Müller-Spahn F, Pragst F, Johnson B, Javors M, Ait-Daoud N, Skipper GE, Spies C, Nachbar Y, Lesch O, Ramskogler K, et al. World Health Organization/International Society for Biomedical Research on Alcoholism study on state and trait markers of alcohol use and dependence: back to the future. Alcoholism, Clinical and Experimental Research. 29: 1268-75. PMID 16088983 DOI: 10.1097/01.Alc.0000171483.93724.96 |
0.485 |
|
| 2005 |
Dawes MA, Johnson BA, Ma JZ, Ait-Daoud N, Thomas SE, Cornelius JR. Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addictive Behaviors. 30: 1630-7. PMID 16084024 DOI: 10.1016/J.Addbeh.2005.07.004 |
0.482 |
|
| 2005 |
Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Archives of Internal Medicine. 165: 1600-5. PMID 16043677 DOI: 10.1001/Archinte.165.14.1600 |
0.41 |
|
| 2005 |
Dawes MA, Johnson BA, Ait-Daoud N, Ma JZ, Cornelius JR. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addictive Behaviors. 30: 1077-85. PMID 15925118 DOI: 10.1016/J.Addbeh.2004.10.011 |
0.459 |
|
| 2005 |
Johnson BA, Roache JD, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y. Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 8: 203-13. PMID 15850499 DOI: 10.1017/S1461145704005036 |
0.336 |
|
| 2005 |
Wurst FM, Alling C, Aradottir S, Pragst F, Allen JP, Weinmann W, Marmillot P, Ghosh P, Lakshman R, Skipper GE, Neumann T, Spies C, Javors M, Johnson BA, Ait-Daoud N, et al. Emerging biomarkers: new directions and clinical applications. Alcoholism, Clinical and Experimental Research. 29: 465-73. PMID 15770123 DOI: 10.1097/01.Alc.0000156082.08248.Ab |
0.463 |
|
| 2005 |
Johnson BA, Swift RM, Addolorato G, Ciraulo DA, Myrick H. Safety and efficacy of GABAergic medications for treating alcoholism. Alcoholism, Clinical and Experimental Research. 29: 248-54. PMID 15714047 DOI: 10.1097/01.Alc.0000153542.10188.B0 |
0.489 |
|
| 2005 |
Johnson BA, Javors MA, Lam YW, Wells LT, Tiouririne M, Roache JD, Ait-Daoud N, Lawson K. Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 29: 15-20. PMID 15610940 DOI: 10.1016/J.Pnpbp.2004.08.014 |
0.334 |
|
| 2005 |
Javors MA, Seneviratne C, Roache JD, Ait-Daoud N, Bergeson SE, Walss-Bass MC, Akhtar FZ, Johnson BA. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 29: 7-13. PMID 15610939 DOI: 10.1016/J.Pnpbp.2004.08.004 |
0.364 |
|
| 2004 |
Johnson BA. Uses of topiramate in the treatment of alcohol dependence. Expert Review of Neurotherapeutics. 4: 751-8. PMID 15853502 DOI: 10.1586/14737175.4.5.751 |
0.511 |
|
| 2004 |
Johnson BA. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. Cns Drugs. 18: 1105-18. PMID 15581381 DOI: 10.2165/00023210-200418150-00005 |
0.512 |
|
| 2004 |
Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcoholism, Clinical and Experimental Research. 28: 1356-61. PMID 15365306 DOI: 10.1097/01.Alc.0000139823.30096.52 |
0.426 |
|
| 2004 |
Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Archives of General Psychiatry. 61: 905-12. PMID 15351769 DOI: 10.1001/Archpsyc.61.9.905 |
0.494 |
|
| 2004 |
Johnson BA. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addictive Behaviors. 29: 1465-79. PMID 15345276 DOI: 10.1016/J.Addbeh.2004.06.014 |
0.467 |
|
| 2004 |
Johnson BA. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opinion On Pharmacotherapy. 5: 1943-55. PMID 15330732 DOI: 10.1517/14656566.5.9.1943 |
0.521 |
|
| 2004 |
Johnson BA. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcoholism, Clinical and Experimental Research. 28: 1137-44. PMID 15318111 DOI: 10.1097/01.Alc.0000134533.96915.08 |
0.498 |
|
| 2004 |
Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. Journal of Clinical Psychopharmacology. 24: 421-8. PMID 15232334 DOI: 10.1097/01.Jcp.0000130555.63254.73 |
0.5 |
|
| 2004 |
Littleton JM, De Witte P, Litten R, Gessa GL, Spanagel R, Kranzler H, Lehert P, Johnson B, Saunders J, Berglund M, Harris A, Anton R, Mann K. Challenges to medications development in treating alcohol dependence: an international perspective. Alcohol and Alcoholism (Oxford, Oxfordshire). 39: 271-5. PMID 15208155 DOI: 10.1093/Alcalc/Agh067 |
0.435 |
|
| 2004 |
Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Mauldin JB. Effects of isradipine on cocaine-induced subjective mood. Journal of Clinical Psychopharmacology. 24: 180-91. PMID 15206666 DOI: 10.1097/01.Jcp.0000115662.45074.C3 |
0.312 |
|
| 2004 |
Johnson BA, Swift RM, Ait-Daoud N, DiClemente CC, Javors MA, Malcolm RJ. Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcoholism, Clinical and Experimental Research. 28: 295-301. PMID 15112937 DOI: 10.1097/01.Alc.0000113409.47937.6C |
0.518 |
|
| 2004 |
McBride WJ, Lovinger DM, Machu T, Thielen RJ, Rodd ZA, Murphy JM, Roache JD, Johnson BA. Serotonin-3 receptors in the actions of alcohol, alcohol reinforcement, and alcoholism. Alcoholism, Clinical and Experimental Research. 28: 257-67. PMID 15112933 DOI: 10.1097/01.Alc.0000113419.99915.Da |
0.485 |
|
| 2004 |
Dawes MA, Johnson BA. Pharmacotherapeutic trials in adolescent alcohol use disorders: opportunities and challenges. Alcohol and Alcoholism (Oxford, Oxfordshire). 39: 166-77. PMID 15082452 DOI: 10.1093/Alcalc/Agh045 |
0.434 |
|
| 2004 |
Johnson BA, Ait-Daoud N, Bowden CL, Willenbring ML. Oral topiramate was effective as an adjunt to standardised medication compliance management in alcohol dependence Evidence-Based Medicine. 9: 24-24. DOI: 10.1136/Ebm.9.1.24 |
0.442 |
|
| 2004 |
Johnson BA. Pharmacotherapy For Promotion Of Abstinence From Nicotine Among Alcohol-Dependent Individuals. Alcoholism: Clinical and Experimental Research. 28. DOI: 10.1097/00000374-200408002-00373 |
0.44 |
|
| 2003 |
Javors MA, Johnson BA. Current status of carbohydrate deficient transferrin, total serum sialic acid, sialic acid index of apolipoprotein J and serum beta-hexosaminidase as markers for alcohol consumption. Addiction (Abingdon, England). 98: 45-50. PMID 14984241 DOI: 10.1046/J.1359-6357.2003.00582.X |
0.452 |
|
| 2003 |
Johnson BA, Ait-Daoud N, Ma JZ, Wang Y. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals. Alcoholism, Clinical and Experimental Research. 27: 1773-9. PMID 14634493 DOI: 10.1097/01.Alc.0000095635.46911.5D |
0.485 |
|
| 2003 |
Johnson BA. The role of serotonergic agents as treatments for alcoholism. Drugs of Today (Barcelona, Spain : 1998). 39: 665-72. PMID 14586482 DOI: 10.1358/Dot.2003.39.9.799475 |
0.517 |
|
| 2003 |
Johnson BA, O'Malley SS, Ciraulo DA, Roache JD, Chambers RA, Sarid-Segal O, Couper D. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. Journal of Clinical Psychopharmacology. 23: 281-93. PMID 12826990 DOI: 10.1097/01.Jcp.0000084029.22282.Bb |
0.386 |
|
| 2003 |
Sloan TB, Roache JD, Johnson BA. The role of anxiety in predicting drinking behaviour. Alcohol and Alcoholism (Oxford, Oxfordshire). 38: 360-3. PMID 12814905 DOI: 10.1093/Alcalc/Agg090 |
0.422 |
|
| 2003 |
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 361: 1677-85. PMID 12767733 DOI: 10.1016/S0140-6736(03)13370-3 |
0.5 |
|
| 2003 |
Enoch MA, Schuckit MA, Johnson BA, Goldman D. Genetics of alcoholism using intermediate phenotypes. Alcoholism, Clinical and Experimental Research. 27: 169-76. PMID 12605066 DOI: 10.1097/01.Alc.0000052702.77807.8C |
0.381 |
|
| 2002 |
Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology. 160: 408-13. PMID 11919668 DOI: 10.1007/S00213-002-1002-9 |
0.505 |
|
| 2002 |
Ait-Daoud N, Johnson BA. Ondansetron with and without naltrexone as a treatment of biologic alcoholism: Concepts and updated findings Addictive Disorders and Their Treatment. 1: 75-80. DOI: 10.1097/00132576-200209000-00001 |
0.528 |
|
| 2001 |
Ait-Daoud N, Johnson BA, Javors M, Roache JD, Zanca NA. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. Alcoholism, Clinical and Experimental Research. 25: 847-9. PMID 11410720 DOI: 10.1111/J.1530-0277.2001.Tb02289.X |
0.456 |
|
| 2001 |
Ait-Daoud N, Johnson BA, Prihoda TJ, Hargita ID. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology. 154: 23-7. PMID 11292002 DOI: 10.1007/S002130000607 |
0.526 |
|
| 2000 |
Johnson BA. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept--an hypothesis. Alcoholism, Clinical and Experimental Research. 24: 1597-601. PMID 11045870 DOI: 10.1111/J.1530-0277.2000.Tb04581.X |
0.473 |
|
| 2000 |
Johnson BA, Roache JD, Javors MA, Diclemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial Journal of the American Medical Association. 284: 963-971. PMID 10944641 DOI: 10.1001/Jama.284.8.963 |
0.508 |
|
| 2000 |
Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: Scientific basis and clinical findings Psychopharmacology. 149: 327-344. PMID 10867960 DOI: 10.1007/S002130000371 |
0.539 |
|
| 1999 |
Johnson BA, Roache JD, Bordnick PS, Ait-Daoud N. Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: A preliminary study Psychopharmacology. 144: 295-300. PMID 10435398 DOI: 10.1007/S002130051007 |
0.318 |
|
| 1992 |
Silverstone PH, Johnson B, Cowen PJ. Does ondansetron attenuate amphetamine-induced behaviour in human volunteers? Psychopharmacology. 107: 140-141. PMID 1534176 DOI: 10.1007/Bf02244979 |
0.308 |
|
| 1992 |
Silverstone PH, Oldman D, Johnson B, Cowen PJ. Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. International Clinical Psychopharmacology. 7: 37-43. PMID 1385603 DOI: 10.1097/00004850-199200710-00005 |
0.301 |
|
| Show low-probability matches. |